全文获取类型
收费全文 | 1125篇 |
免费 | 80篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 35篇 |
妇产科学 | 8篇 |
基础医学 | 143篇 |
口腔科学 | 11篇 |
临床医学 | 107篇 |
内科学 | 310篇 |
皮肤病学 | 13篇 |
神经病学 | 92篇 |
特种医学 | 15篇 |
外科学 | 140篇 |
综合类 | 5篇 |
一般理论 | 3篇 |
预防医学 | 140篇 |
眼科学 | 17篇 |
药学 | 91篇 |
中国医学 | 6篇 |
肿瘤学 | 64篇 |
出版年
2023年 | 22篇 |
2022年 | 31篇 |
2021年 | 78篇 |
2020年 | 44篇 |
2019年 | 38篇 |
2018年 | 51篇 |
2017年 | 38篇 |
2016年 | 39篇 |
2015年 | 32篇 |
2014年 | 52篇 |
2013年 | 57篇 |
2012年 | 81篇 |
2011年 | 83篇 |
2010年 | 39篇 |
2009年 | 48篇 |
2008年 | 65篇 |
2007年 | 83篇 |
2006年 | 54篇 |
2005年 | 64篇 |
2004年 | 48篇 |
2003年 | 58篇 |
2002年 | 30篇 |
2001年 | 6篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 9篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 2篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1980年 | 2篇 |
1978年 | 3篇 |
1977年 | 1篇 |
排序方式: 共有1207条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
15.
16.
Matthias Szabolcs Megan Keniry Laura Simpson Latarsha J. Reid Susan Koujak Sarah C. Schiff Giselle Davidian Scott Licata Sofia Gruvberger-Saal Vundavalli V.V.S. Murty Subhadra Nandula Argiris Efstratiadis Jake A. Kushner Morris F. White Ramon Parsons 《The American journal of pathology》2009,174(1):276-286
Mutations in the phosphatase and tensin homologue (PTEN)/phosphatidylinositol-3 kinase-α (PI3K) signaling pathway are frequently found in human cancer. In addition, Pten+/− mice develop tumors in multiple organs because of the activation of the PI3K signaling cascade. Because activation of PI3K signaling leads to feedback inhibition of insulin receptor substrate-2 (IRS2) expression, an upstream activator of PI3K, we therefore anticipated that IRS2 expression would be low in tumors that lack PTEN. Surprisingly, however, an elevation of IRS2 was often detected in tumor samples in which PTEN levels were compromised. To determine the potential contribution of Irs2 to tumor progression, Pten+/− mice were crossed with Irs2+/− mice. Deletion of Irs2 did not affect the initiation of neoplasia found in Pten+/− mice but suppressed cancer cell growth, proliferation, and invasion through the basement membrane. Deletion of Irs2 also attenuated the expression of Myc in prostatic intraepithelial neoplasia in Pten+/− mice. In addition, the expression levels of IRS2 and MYC were highly correlated in human prostate cancer, and IRS2 could stimulate MYC expression in cultured cells. Our findings provide evidence that the PI3K-activating adaptor Irs2 contributes to tumor progression in Pten+/− mice by stimulating both Myc and DNA synthesis. 相似文献
17.
18.
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C 总被引:21,自引:0,他引:21
Promrat K McDermott DH Gonzalez CM Kleiner DE Koziol DE Lessie M Merrell M Soza A Heller T Ghany M Park Y Alter HJ Hoofnagle JH Murphy PM Liang TJ 《Gastroenterology》2003,124(2):352-360
BACKGROUND & AIMS: CCR5Delta32, a 32-base pair deletion of the CC chemokine receptor (CCR) 5 gene, is associated with slowed human immunodeficiency virus disease progression in heterozygotes and protection against infection in homozygotes. A recent study found a higher than expected frequency of CCR5Delta32/Delta32 in patients with hepatitis C virus infection. The roles of other disease-associated chemokine system polymorphisms have not been evaluated in hepatitis C virus infection. METHODS: Six chemokine system polymorphisms (CCR5Delta32, CCR5 promoter 59029-G/A, CCR2 -64I, RANTES [regulated upon activation, normal T cells expressed and secreted] -403 -G/A, and -28 -C/G and stromal derived factor 1 -3'A) were studied in 417 patients with liver diseases (339 with hepatitis C) and 2380 blood donors. The clinical parameters of hepatitis C virus infection were compared between carriers and noncarriers of each genetic variant. RESULTS: The frequency of CCR5Delta32 homozygosity was 0.8% in whites with hepatitis C virus and 1.1% in controls (P = 0.75). The CCR5Delta32 allele was not associated with any of the clinical parameters of hepatitis C virus infection. Hepatitis C virus-seropositive whites with the RANTES -403-A allele were less likely to have severe hepatic inflammation compared with those without (odds ratio, 0.34; P = 0.03). In multivariate analysis, the CCR5 promoter 59029 -A allele was marginally associated with a sustained response to interferon therapy (odds ratio, 3.07; P = 0.048). CONCLUSIONS: In this cohort, the frequency of CCR5Delta32 homozygosity in patients with hepatitis C was similar to controls. The high prevalence of CCR5Delta32 homozygosity in the hepatitis C virus patients of the earlier study likely reflects resistance to human immunodeficiency virus infection in hemophiliacs rather than a susceptibility to hepatitis C virus infection. Expression of CCR5 and RANTES may be important in the modulation of hepatic inflammation and response to interferon therapy in chronic hepatitis C. 相似文献
19.
Soza A Heller T Ghany M Lutchman G Jake Liang T Germain J Hsu HH Park Y Hoofnagle JH 《Journal of hepatology》2005,43(1):67-71
BACKGROUND/AIMS: Currently, there are no effective therapies available for patients with chronic hepatitis C who have failed to respond to optimal interferon alfa-based regimens. The aims of this pilot study were to assess the antiviral activity and safety of interferon gamma in chronic hepatitis C. METHODS: Patients with chronic hepatitis C, genotype 1, who had not responded to or who had relapsed after therapy with interferon alfa and ribavirin were enrolled in a trial of interferon gamma 1b given in doses of 100, 200 or 400 microg subcutaneously three times weekly for 4 weeks. Frequent blood samples were obtained for HCV RNA levels. RESULTS: Fourteen patients were enrolled. Geometric mean HCV RNA levels remained unchanged. Serum aminotransferase levels also did not change, while there were significant decreases in neutrophil counts (-41% from baseline) and hematocrit (-5%). Low grade fever and malaise were common with the first injection of interferon gamma, but no serious side effects were encountered. CONCLUSIONS: Although relatively well tolerated, interferon gamma in doses of 100-400 microg thrice weekly had no effect on HCV RNA levels in patients with chronic hepatitis C who had failed to achieve a sustained response to interferon alfa-based therapies. 相似文献